Af­ter crit­ics lam­bast­ed Gilead for grab­bing the FDA's spe­cial rare drug sta­tus on remde­sivir, they're giv­ing it back

Two days af­ter Gilead won or­phan drug sta­tus for remde­sivir as a po­ten­tial treat­ment for Covid-19, they’re hand­ing it back. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.